Lista de obras - Maki Tanioka - Dominio Público Uruguay

4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

artículo científico publicado en 2014

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

artículo científico publicado en 2012

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.

artículo científico publicado en 2012

Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

scientific article published on 25 September 2013

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

artículo científico publicado en 2017

Clinical characteristics and outcomes of women with stage IV endometrial cancer.

artículo científico publicado en 2009

Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.

artículo científico publicado en 2003

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

artículo científico publicado en 2011

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

artículo científico publicado en 2018

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

artículo científico publicado en 2014

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors ⬇️

artículo científico publicado el 6 de diciembre de 2011

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

artículo científico publicado en 2010

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.

artículo científico publicado en 2010

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

artículo científico publicado en 2017

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

artículo científico publicado en 2010

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.

artículo científico publicado en 2014

Lista de obras de Maki Tanioka

4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.

Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Clinical characteristics and outcomes of women with stage IV endometrial cancer.

Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors ⬇️

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.